Page 9 - Tim Walbert News Today

Second-Quarter 2022 Results:-- Net Sales of $876.4 Million; Orphan Segment Net Sales Increased 13% to $841.3 Million ---- GAAP Net Income of $61.0 Million; Adjusted EBITDA of $306.6 Million ---- TEPEZZA® (teprotumumab-trbw) Net Sales of $479.8 Million ---- KRYSTEXXA® (pegloticase injection) Net Sales of $167.8 Milli...

--Company Also Makes Fortune Best Workplace for Millennials List for Third Consecutive Year -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named by Seramount (formerly Working

Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named to the Fortune Best Workplaces in Chicago 2022 list, ranking No. 3 in the large company category. The list includes 15 top

Horizon Therapeutics plc (Nasdaq: HZNP) today announced the company has won an International Corporate Social Responsibility (CSR) Excellence Award for its partnership with Gift of Adoption to co-create

Horizon Therapeutics plc has confirmed that the company is seeking to recruit 50 people to work in high-end specialist roles in science and engineering in its…

Rare disease specialist looking to add jobs at corporate level and at new manufacturing site

Rare disease specialist looking to add jobs at corporate level and at new manufacturing site

Horizon Therapeutics Public Limited Company (NASDAQ:NASDAQ:HZNP) Q1 2022 Earnings Conference Call May 04, 2022 08:00 AM ET Company Participants Tina Ventura - Senior Vice President, Chief...

Horizon Therapeutics plc (Nasdaq: HZNP) today announced the kickoff of the second annual global innovation challenge, The Horizon Prize powered by MIT Solve. The Horizon Prize poses a unique question

Horizon Therapeutics plc today announced that it has been recognized as one of the Best Workplaces in Ireland 2022 by Great Place to Work Ireland, ranking No. 9 in the medium company... | March 24, 2022